CALLDORADO
8.9.2021 11:29:08 CEST | Business Wire | Press release
Calldorado has acquired longstanding partner Appvestor in a deal that will give its community of app developers instant access to advanced user acquisition tools.
The two companies make a good fit. Both are dedicated to helping app makers grow but in different ways. Calldorado’s unique technology helps Android developers keep existing user bases active and monetize them. Meanwhile, Appvestor’s AI-powered tools help them find new customers.
Appvestor was established in 2017 to build a technology engine that deploys machine learning and predictive algorithms to establish the best destinations for paid marketing campaigns. Its complete service to developers includes:
- A technology engine that maps campaign progress against revenue, conversion, and retention at a user level.
- Experience in running marketing campaigns that deliver large volumes of new users and the highest return on investment.
- Access to creative resources including studio and production.
- Expertise in ASO (App Store Optimization), which boosts the impact of campaigns and the number of customer conversions.
Calldorado has been working closely with Appvestor since its launch. Mathias Schroeder, co-CEO and co-founder of Calldorado, believes the buy-out is a logical move for both parties. He says: “Our tech does a brilliant job of keeping app users engaged. But it doesn’t find new ones. That’s why we have worked with many user acquisition platforms in the past.
"Appvestor was always the best. It’s the only one with predictive algorithms that can dynamically adjust a marketing campaign to maximize return on investment at all times. Paid user acquisition is a key strategic asset for us, so acquiring Appvestor makes perfect sense. We can’t wait to combine the two companies’ skills into a service that can really help scale our first-party and customer apps.”
The acquisition comes at a time of rapid growth in the app market. Total app downloads across both iOS and Google Play hit 130 billion (1 ). This was a 10% increase on 2019.
Meanwhile, total consumer spend on apps (in-app purchases, subscriptions, and premium apps) reached $143 billion in 2020 – up 20% in a year. App Annie believes the total could hit $270 billion by 2025.
The buoyant app market has fuelled a fast-growing app install ad sector. Developers increasingly rely on paid marketing to drive installs. So much so that analysts expect the total spend to rise from $57.8 billion in 2019 to $118 billion in 2022 (2).
About Calldorado
Calldorado’s unique user activation and monetization technology, the Caller SDK, helps Android app publishers keep their app user bases active, drives incremental traffic, and maximizes app revenue. Calldorado also publishes first-party apps; it launched its own content business with the acquisition of CIAmedia in 2018. A year later it acquired the call enrichment specialist adaffix. Calldorado was established in 2016 with headquarters in Denmark and is privately held.
1. Source: App Annie – State of Mobile 2021 https://www.appannie.com/en/go/state-of-mobile-2021/
2. Source: Appsflyer https://www.appsflyer.com/blog/trends-insights/app-install-ad-spend/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005536/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
